Search research articles
Contact Us
Filters
Showing results (321-330 of 336) with videos related to
Page
of 34
Sort By:
Cancer Research Communications
|
June 28, 2023
Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Anne-Sophie Sertier, Anthony Ferrari, Roxane M Pommier, et al.
Translational Oncology
|
July 1, 2026
Baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer: Results from a GINECO/GINEGEPS study of the randomized phase II CHIVA trial
Pauline Corbaux, Olivier Colomban, Gaelle Lescuyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 15, 2026
Circulating tumor DNA for prognostication and monitoring in patients with metastatic endometrial carcinoma treated with olaparib: validation in the GINECO-UTOLA trial
Guillaume Beinse, Valerie Taly, Alexandra Leary, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 16, 2014
Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15)
Gwenaelle Gravis, Patricia Marino, Florence Joly, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 3, 2026
Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review
Marit Ahrens, John Haanen, Laurence Albiges, et al.
Gynecologic Oncology
|
January 27, 2023
Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial
Gwénaël Ferron, Gaëtan De Rauglaudre, Stéphanie Becourt, et al.
Nature Communications
|
August 26, 2025
Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial
Florence Joly, Alexandra Leary, Isabelle Ray-Coquard, et al.
Journal of the National Cancer Institute
|
April 25, 2026
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25)
Florence Joly, Amélie Anota, Sylvie Chabaud, et al.
The Lancet. Oncology
|
January 12, 2013
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial
Gwenaelle Gravis, Karim Fizazi, Florence Joly, et al.
The Lancet. Oncology
|
April 20, 2020
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial
Jacobus Pfisterer, Catherine M Shannon, Klaus Baumann, et al.
Page
of 34
Search research articles
Search
Showing results (321-330 of 336) with videos related to
Sort By:
Page
of 34
Cancer Research Communications
|
June 28, 2023
Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas
Anne-Sophie Sertier, Anthony Ferrari, Roxane M Pommier, et al.
Translational Oncology
|
July 1, 2026
Baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer: Results from a GINECO/GINEGEPS study of the randomized phase II CHIVA trial
Pauline Corbaux, Olivier Colomban, Gaelle Lescuyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 15, 2026
Circulating tumor DNA for prognostication and monitoring in patients with metastatic endometrial carcinoma treated with olaparib: validation in the GINECO-UTOLA trial
Guillaume Beinse, Valerie Taly, Alexandra Leary, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 16, 2014
Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15)
Gwenaelle Gravis, Patricia Marino, Florence Joly, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 3, 2026
Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review
Marit Ahrens, John Haanen, Laurence Albiges, et al.
Gynecologic Oncology
|
January 27, 2023
Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial
Gwénaël Ferron, Gaëtan De Rauglaudre, Stéphanie Becourt, et al.
Nature Communications
|
August 26, 2025
Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial
Florence Joly, Alexandra Leary, Isabelle Ray-Coquard, et al.
Journal of the National Cancer Institute
|
April 25, 2026
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25)
Florence Joly, Amélie Anota, Sylvie Chabaud, et al.
The Lancet. Oncology
|
January 12, 2013
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial
Gwenaelle Gravis, Karim Fizazi, Florence Joly, et al.
The Lancet. Oncology
|
April 20, 2020
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial
Jacobus Pfisterer, Catherine M Shannon, Klaus Baumann, et al.
Page
of 34